as log scale, showed that there are three elimination phases and there is a very long gamma phase. In this study, our data suggest that the long gamma phase is due to TPPU binding selectively to sEH. Although it is possible that the long gamma phase might be an experimental artifact, our identical experiment with sEH KO mice that did not show the same long gamma phase, confirmed that the obtained result is real. Male mice (n=6) were treated by subcutaneous injection (0.3 mg/kg dissolved in PEG400, 100 to 110 µL of total injection volume). The data are mean ± standard error of the mean (SEM). The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). The data are mean ± SEM. The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA).
Figure S5
Determination of the optimum dose of TCPU, a displacement inhibitor B, to be used for the displacement of TPPU. The tested inhibitor for the in vivo displacement assay is 3 mg/kg based on our escalating dose study of displacement inhibitor B. Our data show that at 3 mg/kg of TCPU, the AUC of the 2 nd displacement peak of TPPU reaches the maximum and further increasing the dose of TCPU to 10 mg/kg does does not increase the AUC of the 2 nd displacement peak of TPPU. Male mice (n=3 to 6) were treated by subcutaneous injection (0.3 mg/kg of TPPU or 0.3 mg/kg to 10 mg/kg of TCPU dissolved in PEG400, 100 to 110 µL of total injection volume depends on the weight of the mouse).
The data are mean ± SEM. The graphics and statistics were prepared by SigmaPlot (SysTat Software, San Jose, CA). we ran the displacement assay in rat. Like in the mouse study, the in vivo displacement assay in rat showed that the inhibitor (TCPU) with short tR had much smaller 2 a elogP, IC50 and t1/2 were reported before and IC50 were determined in rat sEH. 22 The results are the average of triplicates with ± SEM.
b The mice (n=3 to 6) were treated by subcutaneous injection with inhibitor at the desired dose (0.3 to 20 mg/kg dissolved in PEG400.
c The pharmacokinetic parameters were calculated by Winonlin based on the best-fitted models. Abbreviation: elogP stands for experimental logP.
Experimental Section
All the experiments presented in this manuscript are generally safe and no unexpected or unusually high safety hazards were encountered.
Pharmacokinetic (PK) protocol for an in vivo displacement assay in mouse
The animal experiments were performed based on the protocols approved by the Animal Use and Care Committee of University of California at Davis. Male C57BL/6J mice or C57BL/6J soluble epoxide hydrolase knock-out mice (n= 6, 8 to 12-week old, 24-30g were used. We did not observe different PK profile of sEH inhibitor with mice at different ages.
See Figure S1 ). Mice were purchased from Charles River Laboratories for the PK experiments. Inhibitor (TPPU or TPAU) was dissolved in 100% PEG400 at the desired dose (0.3 or 1 mg/kg respectively) with warming at 60˚C overnight to give a clear solution. 
Analysis of the sEH inhibitors in blood samples
The blood samples were prepared according to the published method by Liu et al. Step 
Chemical Synthesis
All chemicals and solvents purchased from commercial suppliers were used directly without purification. All syntheses were carried out in dry argon atmosphere with ovendried reaction vessels unless specified. Reactions were monitored by thin-layer chromatography (TLC, on silica gel, 60Å, glass slides, fluorescent indicator coated, spots were visible under UV-light (254 nm) or stained with potassium permanganate solution).
Column chromatography was conducted on silica gel.
1 H-NMR spectra were performed on a Varian QE-300 spectrometer with deuterated chloroform (CDCl3, ∂ = 7.24 ppm) or deuterated dimethyl sulfoxide (DMSO-d6, ∂ = 2.50 ppm).
The purity of the inhibitors reported in this manuscript was determined either by 1) HPLC-UV using Shimadzu Prominence HPLC coupled with Phenomenex Kinetex C18 reverse phase column (4.6 x 250 mm, 5 µm, 100Å) using 230 nm for detection with linear gradient from 5% water in acetonitrile to 100% acetonitrile in 30 min; and by 2) 1 H-NMR. The lowest purity was reported. The inhibitors were dissolved in ethanol at 100 µM and 10 µL was injected to HPLC. The purity was estimated based on the inhibitor's peak area at 230 nm relative to the total peak area at 230 nm using HPLC-UV. The syntheses of most compounds, have been reported elsewhere.
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The synthesis of 1-(1-((λ
2,6-Difluorophenyl isocyanate (270 mg, 1.7 mmol) and 1-Boc-4-aminopiperidine (393 mg, 2.0 mmol) was dissolved in DCM (8 mL). Reaction was stirred for 18 hours and was 
The synthesis of 1-(2,6-difluorophenyl)-3-(piperidin-4-yl)urea (2)
To remove the Boc protecting group, 1 (286 mg, 0. 
Biochemistry
Expression and purification of recombinant sEH followed the published procedure. 5 The purity of the mouse sEH was higher than 95% as reported before. The IC50 of sEH inhibitors were determined by published method. [6] [7] IC50s of the inhibitor, the concentration of the inhibitor that inhibits 50% of the enzyme activity, were determined with the linear regression of at least 5 datum points with minimum of two points in the linear region of the curve on either side of the IC50.
Measurement of Ki using FRET displacement assay
The FRET displacement assay was carried out based on the published procedure.
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Briefly, to avoid leaching of fluorescence impurities from the plastic container and nonspecific binding to sEH inhibitors, the inhibitors were dissolved in DMSO and stored in glass vials.
1) Preparation of the FRET displacement assay
The 96 well-plate for the assay was pre-incubated in sodium phosphate buffer (PB, 100 mM sodium phosphate, 0.01% gelatin, pH 7.4) for at least 8h in order to pre-coated the 96 well-plate with gelatin to prevent sEH inhibitor and sEH from being absorbed by the plastic. The buffer was discarded, and the plate was ready to be used 2) High-throughput Ki determination
The sEH was further diluted to 20 nM by PB (100 mM sodium phosphate, pH 7.4). ACPU (one equivalent to sEH in the solution, 10 mM stock in ethanol, Figure S18 ) was added to the sEH solution. The sEH:ACPU solution was mixed thoroughly and was incubated for 2h at rt in the dark. The sEH:ACPU mixture (20 nM each, 100 mM sodium phosphate, pH 7.4, 150 µL) was added to each well. The fluorescent baseline (F0) (λexcitation : 280 nm, λemission : 450 nm) of the samples was measured after z position and gain were fully optimized by the fluorometer. The z position and gain were noted and were used as the setting for measuring the sample fluorescent after the inhibitor was added. DMSO which is the solvent used for the inhibitor has been reported to quench the fluorescence.
Therefore, 1% DMSO in PB was served as a control (FDMSO). The desired amount of inhibitor was added to the first well. The desired concentration of the inhibitor in the first well was two-time of the concentration where 100% of the sEH was bound to the inhibitor.
The first well was then diluted by 2-fold with the PB buffer and was then futher diluted 2-fold across the rest of the row of well (12 wells in total). 12-datum points which corresponding to 12 different concentration of the inhibitor is generally sufficient data to caculate an accurate Ki of the inhibitors. The samples were then incubated at 30˚C for 1.5h. The fluorescence (λexcitation = 280 nm, λemission = 450 nm) of the samples were then measured using the z position and gain setting that was previously optimized. The obtained fluorescence data were transformed as below and the transformed data were used to determine the Ki of the inhibitor based on the published procedure without modification. [2] [3] The data manipulation and Ki calculation were based on the original paper by Wang et al. with modifications suggested by Roehrl et al. [8] [9] Initiated fluorescence = FDMSO (well X) / F0 (well X) Saturated fluorescence = Fat the saturated concentration (well X) / F0 (at well X) Observed fluorescence = F(well X) / F0 (well X)
koff measurement procedure
The koff was determined as described before. [2] [3] Briefly, the sEH (8 µM) was pre-incubated with the inhibitor (8.8 µM, 100 mM PB buffer, pH 7.4) for 2h at rt. The sEH:inhibitor complex was then diluted by 40-fold with ACPU solution (20 µM, 100 mM Sodium phosphate buffer, pH 7.4). The fluorescence (λexcitation = 280 nm, λemission = 450 nm) was monitored immediately for 5100s every 30s. The fluorescence (λemission = 450 nm) data was plotted against time (s). The resulting curve was fitted to single exponential growth and the relative koff was calculated.
Determination of plasma to blood ratio of sEH inhibitor
The mouse blood was a generous gift from Dr. Liby. Briefly, selected sEH inhibitor (0.5 mM, 0.3 µL, DMSO stock) was added to heparinized freshly connected mouse blood (300 µL). The blood sample was incubated at 37˚C and shaken at 500 rpm for 1h. A sample from whole blood (50 µL) was collected and the rest of the whole blood was centrifuged at 1,500 g in microfuge at 4 ˚C for 10 min. The plasma sample (50 µL) was collected. An internal standard (1 µL, an sEH inhibitor which is structurally similar with similar log P as the tested inhibitor) was added to both plasma and whole blood sample and was mixed in the shaker for 1 min at 1000 rpm. Both samples were then extracted with ethyl acetate (200 µL) twice. The collected organic layers were combined and was evaporated under vacuum. The dried samples were reconstituted by adding 50 µL of external standard (50 µL, 100 nM CUDA (a sEH inhibitor). The samples were then storage at -20 ˚C until LC/MSMS analysis.
